Challenges of Convalescent Plasma Infusion Therapy in Middle East Respiratory Coronavirus Infection: A Single Centre Experience

Ko, J.H.; Seok, Hyeri; Cho, Sun Young; Ha, Young Eun; Baek, Jin Yang; Kim, So Hyun; Kim, Yae Jean; Park, Jin Kyeong; Chung, Chi Ryang; Kang, Eun Suk; Cho, Duck; Müller, Marcel A.; Drosten, Christian; Kang, Cheol In; Chung, Doo Ryeon; Song, Jae Hoon; Peck, Kyong Ran

doi:10.3851/imp3243

Cited by 314 publications

(279 citation statements)

References 16 publications

Supporting

Mentioning

265

Contrasting

Unclassified

Order By: Relevance

“…In the 2015 Korean outbreak, three of 13 patients with MERS with respiratory failure were given four infusions of convalescent plasma. 107 Two of three showed neutralising activity. Donor plasma with a plaque reduction neutralisation test (PRNT) titre of 1/80 had a meaningful serological response after convalescent plasma infusion, while that with a PRNT titre of 1/40 did not.…”

Section: Convalescent Plasmamentioning

confidence: 96%

Middle East respiratory syndrome

et al. 2020

View full text Add to dashboard Cite

The Middle East respiratory syndrome coronavirus (MERS-CoV) is a lethal zoonotic pathogen that was first identified in humans in Saudi Arabia and Jordan in 2012. Intermittent sporadic cases, community clusters, and nosocomial outbreaks of MERS-CoV continue to occur. Between April 2012 and December 2019, 2499 laboratory-confirmed cases of MERS-CoV infection, including 858 deaths (34·3% mortality) were reported from 27 countries to WHO, the majority of which were reported by Saudi Arabia (2106 cases, 780 deaths). Large outbreaks of human-to-human transmission have occurred, the largest in Riyadh and Jeddah in 2014 and in South Korea in 2015. MERS-CoV remains a high-threat pathogen identified by WHO as a priority pathogen because it causes severe disease that has a high mortality rate, epidemic potential, and no medical countermeasures. This Seminar provides an update on the current knowledge and perspectives on MERS epidemiology, virology, mode of transmission, pathogenesis, diagnosis, clinical features, management, infection control, development of new therapeutics and vaccines, and highlights unanswered questions and priorities for research, improved management, and prevention.

show abstract

Section: Convalescent Plasmamentioning

confidence: 96%

Middle East respiratory syndrome

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Known risks are 500 mL convalescent serum, resulting in a reduction in serum virus titer, and each survived (21). Three patients with MERS in South Korea were treated with convalescent serum, but only two of the recipients had neutralizing antibody in their serum (22). The latter study highlights a challenge in using convalescent sera, namely, that some who recover from viral disease may not have high titers of neutralizing antibody (23).…”

Section: Historical Precedentsmentioning

confidence: 99%

The convalescent sera option for containing COVID-19

Casadevall¹,

Pirofski²

2020

Journal of Clinical Investigation

899

949

View full text Add to dashboard Cite

“…Antibodies against RBD and S2 domain of SARS-CoV and MERS-CoV S proteins have been found effective in neutralizing infections of permissive cell lines in vitro [52][53][54][55]. In addition, neutralizing antibodies were capable of treating infections in experimental animals and in infected patients during these major outbreaks [56][57][58][59]. In one study, several SARS-CoV RBD-specific monoclonal antibodies did not bind to SARS-CoV-2 S protein [43].…”

Section: Of 15mentioning

confidence: 99%

Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks

et al. 2020

View full text Add to dashboard Cite

Coronaviruses (CoVs) are RNA viruses that have become a major public health concern since the Severe Acute Respiratory Syndrome-CoV (SARS-CoV) outbreak in 2002. The continuous evolution of coronaviruses was further highlighted with the emergence of the Middle East Respiratory Syndrome-CoV (MERS-CoV) outbreak in 2012. Currently, the world is concerned about the 2019 novel CoV (SARS-CoV-2) that was initially identified in the city of Wuhan, China in December 2019. Patients presented with severe viral pneumonia and respiratory illness. The number of cases has been mounting since then. As of late February 2020, tens of thousands of cases and several thousand deaths have been reported in China alone, in addition to thousands of cases in other countries. Although the fatality rate of SARS-CoV-2 is currently lower than SARS-CoV, the virus seems to be highly contagious based on the number of infected cases to date. In this review, we discuss structure, genome organization, entry of CoVs into target cells, and provide insights into past and present outbreaks. The future of human CoV outbreaks will not only depend on how the viruses will evolve, but will also depend on how we develop efficient prevention and treatment strategies to deal with this continuous threat.

show abstract

Challenges of Convalescent Plasma Infusion Therapy in Middle East Respiratory Coronavirus Infection: A Single Centre Experience

Abstract: For effective CP infusion in MERS, donor plasma with a neutralization activity of a PRNT titre ≥1:80 should be used. ELISA IgG could substitute for the neutralization test in resource-limited situations.

Cited by 314 publications

References 16 publications

Middle East respiratory syndrome

Middle East respiratory syndrome

The convalescent sera option for containing COVID-19

Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks

Contact Info

Product

Resources

About